Ordering Recommendation
Optimize drug therapy and monitor patient adherence.
Mnemonic
Methodology
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Wed, Sat
Reported
1-5 days
New York DOH Approval Status
Specimen Required
Pre-dose (trough) draw - At steady state concentration.
Plain Red. Also acceptable: Lavender (EDTA) or Pink (K2EDTA).
Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Refrigerated.
Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).
Ambient: 2 weeks; Refrigerated: 2 weeks; Frozen: 2 weeks
Reference Interval
Effective June 7, 2021
Therapeutic Range (Aripiprazole and Dehydroaripiprazole) | 150-500 ng/mL |
Toxic range (Aripiprazole and Dehydroaripiprazole) | Greater than or equal to 1000 ng/mL |
Interpretive Data
The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Adverse effects to aripiprazole therapy may include headache, nausea, somnolence and blurred vision.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
Note
Hotline History
Hotline History
CPT Codes
80342 (Alt code: G0480)
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
2007946 | Aripiprazole Serum/Plasma | 38893-4 |
2007947 | Dehydroaripiprazole, Serum/Plasma | |
2007948 | Total Aripiprazole and Metabolite S/P |
Aliases
- Abilify